Mayo Clinic Laboratory and Pathology Research Roundup: Nov. 28

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.


Featured Abstract

No Difference between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients with Symptomatic Celiac Disease

CeliacDiseaseDiagnosisGluten ingestion leads to symptoms and small intestinal mucosal injury in patients with celiac disease. The only option is the strict lifelong exclusion of dietary gluten, which is difficult to accomplish. Mayo Clinic researchers performed a phase 2 study of the ability of latiglutenase, an orally administered mixture of two recombinant gluten-targeting proteases, to reduce mucosal morphometric measures in biopsies from patients with celiac disease. The double-blind, placebo-controlled, dose-ranging study assessed the efficacy and safety of latiglutenase in 494 patients with celiac disease (with moderate or severe symptoms) in North America and Europe. Patients with documented moderate or severe symptoms and villous atrophy were randomly assigned to groups given placebo or 100, 300, 450, 600, or 900 mg latiglutenase daily for 12 or 24 weeks. In modified intent to treat population, there were no differences between latiglutenase and placebo groups in change from baseline in villous height:crypt depth ration, numbers of IELs, or serologic markers of celiac disease. All groups had significant improvements in histologic and symptom scores. According to the results, latiglutenase did not improve histologic and symptom scores when compared to placebo. There were no significant differences in change from baseline between groups. The case was published in Gastroenterology.


Published to PubMed This Week

kschrib

Kelley Schreiber

Kelley Schreiber is a Marketing Channel Manager at Mayo Medical Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her new kitten, and exploring new foods.